Streptomyces produce a series of structurally novel antitumor agents that contain an unusual phosphate ester, an α, β-unsaturated-δ−lactone and either a conjugated linear diene or triene chain (1). Fostriecin ( Fig. 1 ) and the structurally related PD 113,270 and PD 113,271 are three related natural products produced by Streptomyces pulveraceus subsp. fostreus ATTC 31906 (2,3). Fostriecin inhibits DNA topoisomerase II (IC 50 40 5 mM)(4) and is also a potent and selective inhibitor of protein phosphatases 1 (PP1), 2A (PP2A) and PP4 (IC 50 45 mM, 1.5 nm and 3.0 nm, respectively)(1,5). The latter activity is attributed to the efficacious in vivo antitumor activity of fostriecin, as well as its in vitro activity against leukemia, lung, breast and ovarian cancer. The same activity likely also permits fostriecin to limit myocardial infarct size and to protect cardiomycetes 10 during ischemia (6-8). Recent evidence suggests that PP2A has a role in regulating cell death by apoptosis, activation of natural killer cells and cytotoxic T-lymphocytes involved in tumor surveillance, and even transcription and replication of human immunodeficiency virus-1 (HIV1) (9). For these reasons selective protein phosphatase inhibition has been suggested as a clinically unexplored novel mechanism, worthy of 15 pursuit for the introduction of a new class of antitumor or even antiviral agents (1, 5, 9) .
substituent (C-18) esterified with a wide array of carboxylic acids (ranging in length for 4 to 9 carbons) (10) (11) (12) (13) . The phoslactomycins and leustroducsins all exhibit antifungal activity (1, 10, 13, 14) . More importantly, these compounds like fostriecin are potent and highly selective inhibitors of PP2A (IC 50 values raging from 3.7-5.8 µM), as compared to PP1 (IC 50 > 1mM) (15) . Most recently, the PP2A inhibition activity of phoslactomycin 5 has been shown to inhibit tumor metastasis through augmentation of natural killer cells (16) .
The unique and selective biological activity of this class of natural products has attracted considerable interest in recent years. Phase I clinical trials of fostriecin were 10 suspended, before either dose-limiting toxicities or therapeutic plasma levels were attained, due to inherent drug instability and unpredictable purity in the clinical supply of the natural product (1, 4) . In an attempt to address these limitations and further develop this class of novel antitumor agents, no less than six elegant total syntheses of fostriecin have been developed over a short two year period (5, (17) (18) (19) (20) (21) . A complementary approach 15 for developing these agents can come through gene manipulation of the natural biosynthetic process. In all cases, production of numerous analogs complicates the isolation process and the purity of the product, as well as negatively impacting yields (2, 14, 22) . These analogs are based on variations in the level of hydroxylation and, in the case of the PLMs and leustroducsins, esterification of the resulting secondary alcohol 20 with a series of different carboxylic acids (this modification does not significantly impact either antifungal activity or binding to PP2A). Using a PLM producing strain, Streptomyces sp. HK-803, we have carried out incorporation study of [7- 13 C]CHC which 5 suggests PLM A, PLM C-F are derived from a hydroxylation of PLM B. The entire 75 kb of phoslactomycin biosynthetic gene cluster has been identified and sequenced, including a gene plmS 2 encoding the cyctochrome p450 monooxygenase responsible for this hydroxylation. Application of a new PCR-targeting technology (23) in this strain allowed rapid gene replacement of plmS 2 . The resulting mutant strain, NP1, produces 5 only PLM B, at 6-fold higher levels than the wild-type strain. This mutant will serve as a starting point for engineering strains capable of producing fostriecin and PLM analogs.
EXPERIMENTAL PROCEDURES

Strains and culture conditions
All E. coli strains used in this study were grown following standard protocols (24) . The PLM-producer Streptomyces sp. HK-803 (13) was grown at 28°C in SY medium (1.0% soluble starch, 0.1% yeast extract, 0.1% N-Z amine 5 type A) at pH 7.0. The PLM production medium was 2.0% glucose, 0.1 % beef extract, 1.0% soybean flour, 0.2% NaCl, 0.005% K 2 HPO 4 , 0.2% L-phenylalanine at pH 7.0. A loop-full of Streptomyces sp. HK-803 spores (from an SY agar plate) was inoculated into a baffled 500 ml flask containing 70 ml of the production medium and were incubated at 28°C in the dark for 96 hrs on a rotary shaker at 170 rpm. 10
Analyses of PLM production The culture filtrates and mycelial extracts of Streptomyces sp. HK-803 wild type and the mutant NP1 were worked up as previously described (13) .
HPLC was performed on a system equipped with a Waters TM 600 pump and a Waters 996 photodiode array detector using a following conditions: column, Senshu Pak PEGASIL ODS (4.6 x 250 mm for analytical HPLC and 20 x 250 mm for preparative HPLC); 15 solvent, acetonitrile/0.05% HCO 2 H (40/60); flow rate, 1 ml/min for analytical HPLC and 9 ml/min for preparative HPLC; detection at UV 235 nm. Pure PLM standards were used to generate a standard curve for determining PLM production in both the wild type and was carried out with unlabeled PLMs and allowed the contributions of natural abundance 15 13 C and [7- 13 C]CHC to be separated in the standard manner. The amount of each 13 C labeled PLM derived from [7- 13 C]CHC was determined as a percentage of that entire analog pool. The location of the 13 C label was confirmed by 13 C-NMR analyses of HPLC purified PLM B, E and F (see above) using previously published 13 C assignments (10). Streptomyces genetics (27) . A genomic library was constructed by using Supercos-1 cosmid vector as recommended in the manufacturer protocol (Stratagene). About 2000 cosmid clones was probed by using the DNA of a digoxigenin-labeled chcA gene (28).
Preparation of the digoxigenin probes, and the subsequent hybridization and detection were performed as recommended in the manufacturer protocol (Roche). The overlapping 5 cosmid clones identified by the chcA probe were sequenced to completion using the TOPO shotgun subcloning kit (Invitrogen). Automated DNA sequencing was performed on an ABI Prism 3700 DNA sequencer at DNA core facility of Medical College of Virginia, Viriginia Commonwealth University. The DNA sequences were assembled using SeqMan II (DNAStar Inc.). The assembled DNA and deduced protein sequences 10 were analyzed with MacVector 7.0 software (Accelrys) and FramePlot (29) and compared with sequences in the public databases using the BLAST suite of programs (30) . 2 The plmS 2 gene of the PLM biosynthetic gene cluster was Approximately half of this level of labeling (21-28%) was observed for PLM A, PLM D, PLM E and PLM F, consistent with these analogs containing only one putative CHCderived unit. Curiously, almost 48% of the PLM B was labeled by [7- 13 C]CHC.
Targeted disruption of plmS
Consistent with these observations a 13 C-NMR spectra (125 MHz, CD 3 OD) of the purified PLM-E showed strongly enhanced signals at the predicted sites, C-15 (δ 139. 9 20 ppm) and C-1' (δ 177.3 ppm), indicating that CHC is the precursor of both cyclohexane moieties. Strong and exclusive enrichments of the C-15 (δ 138.2 ppm) was observed in was comparable to that determined from the LC-MS analyses. These observation demonstrate that a coenzyme A activated CHC (CHC-CoA) is the likely starter unit used for biosynthesis of all PLMs. A pathway from shikimic acid to CHC-CoA has been delineated in the ansatrienin producer, Streptomyces collinus (31) . The corresponding biosynthetic genes have recently been identified (33, 34) . 5
Isolation and characterization of the PLM biosynthetic gene cluster
The PLM biosynthetic gene cluster from the Streptomyces sp. HK-803 was identified from a cosmid library of genomic DNA using the chcA gene (28) from CHC-CoA biosynthetic gene cluster of S. collinus as a probe. A cosmid clone 3A11 thus identified was used as a 10 probe to identify two overlapping cosmids, 10B4 and 3E5 (Fig. 2) . These three cosmids (36) . A total of four large ORFs encoding the core PLM PKS were also identified (Fig. 3) . PLM1 contains an initiation domain, presumably responsible for loading the CHC-CoA, and the first extension module (Fig. 3) , while PLM2-3 has two modules containing the appropriate predicted catalytic activitities for catalyzing the second and third extension steps. The remaining components, PLM4 -5 PLM7, each contain a single module. PLM7 has a thioesterase domain, consistent with a role in catalyzing the last extension step and subsequent release of the polyketide chain by formation of the α,β-unsaturated δ-lactone (formation of a 6-membered lactone is unusual as most TE domains studied to date catalyze formation of large 12-14 macrolactone structures under natural conditions) (37, 38) . Two of the PKS polypeptides 10 PLM4 and PLM6 contain the same catalytic domains, precluding unambiguous assigment in this process. One of many interesting features of the PLM PKS cluster is that it contains only three dehydratase domains, yet produces a compound with three Z and one E double bonds (PLM7 does not contain the predicted dehydratase domain). Virtually all known cases in which a PKS modules has a ketoreductase and a dehydratase activity 15 result in formation of E-double bonds (39) . It has been suggested that a stereochemical configuration of the product derived from the KR-domain may control the double bond geometry. A diagnostic Asp residue has been proposed for prediciting the stereospecificity of PKS KR domains and, by extension, the double bond configuration for products from cognate DH domains (39) . We constructed a multiple alignment of the 20 seven KR domains of the PLM PKS and found this model alone was only partially predictive of the stereochemical configuration of the PLM product.
The PLM gene cluster also contains genes which encode a separate type II TE protein (plmT 8 ), recently established to have an important role in editing and proofreading PKSs (40) , and a crotonyl CoA reductase (plmT 7 ), presumably required for providing the ethylmalonyl CoA extender unit used in the fourth and sixth extension steps. The plmT 5 gene product has some sequence identity with homoserine kinases and 5 is likely responsible for phosphorylation of the C-9 hydroxyl group, and providing biological activity to PLM. Analysis of the gene cluster also predicts an oxidoreductase (plmT 8 ) and aminotransferase (plmT 1 ), likely invovled in replacement of a hydroxyl group of a C-8 hydroxyethyl side chain with an amine. The gene cluster also contains numerous other genes involved in regulation and resistance. A detailed analysis of the 10 entire PLM gene cluster will be described elsewhere. 2 Analysis of the PLM biosynthetic gene cluster, together with results of the biosynthetic incorporation study, indicated that three hydroxylation steps (C-18, C-8 and the C-8 ethyl side-chain) occur after assembly of the 15 polyketide chain from the CHC-derived starter unit. Analysis of the PLM biosynthetic gene cluster revealed two ORFs, plmT 4 and plmS 2 , which both encode proteins with high sequence similarity to each other (38% identity and 53% similarity) as well as cytochrome P-450 monooxygenases from several microorganisms, including those involved in modification of streptomycetes natural products (41) . We reasoned that 20 replacement of one of these genes would provided a strain blocked in hydroxylation of C-18 of PLM. With the caveat that the other hydroxylations are catalyzed by the second monoxygenase the mutant strain should produce exclusively PLM B.
PCR-targeted gene disruption of plmS
There are numerous different approaches for probing the secondary metabolic gene clusters through targeted gene disruptions. These approaches typically involve in vitro generation of suitable gene disruption vectors, introduction of these into the host using methods such as conjugation or transformation, and an extensive screening process to find the desired allelic replacement (42, 43) . This entire process can take several 5 months even when methodologies have been developed for the strain. For strains which have not previously been characterized or are not genetically amenable, the process can be substantially longer (44, 45) . We applied a new PCR-targeted gene replacement, 
Enhanced and selective production of PLB by the plmS 2 mutant
The plmS 2 mutant (NP1) was grown under under standard conditions alongside the wild type PLM producer.
After four days of fermentation both cultures were purified by ion exchange chromatography and analyzed by reversed-phase HPLC. The wild type strain produced a 5 mixture of PLMs (A-F), with a total yield of PLMs of 7 mg/ml (Fig. 4) . In stark contrast the NP1 mutant produced only PLM B at approximately 6-fold higher levels (10 mg/ml) than observed for the wild type (<1.6 mg/L) . The PLM B titer in the NP1 mutant exceeds cluster for a potent and selective protein phosphatase inhibitor. Analysis and subsequent manipulation of this gene cluster has allowed for the rational engineering of a strain which produces only one analog, PLM B, at significantly higher yields than the wild type strain. Some of the key drawbacks to continued development of this class of naturallyoccuring compounds including low fermentation titers and resolution of the various analogs produced in the fermentation (both contributing to concerns with drug purity), have now been overcome. Cloning of the PLM biosynthetic gene cluster and creation of a strain producing only PLM B also sets the stage for generation of novel compounds with 5 improved stability, activity, and selectivity. As such this work represets a complementary approach to the widespread synthetic approaches directed towards this class of compounds (5, (17) (18) (19) (20) (21) . One of the key structural differences between PLMs and fostriecin is the C-8 ethylamine substituent, which may contribute to less potent activity (15) .
Inactivation of the plmT 1 gene predicted to be responsible for incorporation of this amino 10 group into the PLM structure should allow for the generation of a novel hybrid structure bearing features of both fostriecin and PLM. Other hybrid natural products may be obtained by combining different PKS components from the two biosynthetic gene clusters. These avenues of research are currently being pursued and will be reported in due course . 15 This work has also demonstrated the utility of the PCR-targeted gene replacement 
